These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30126548)

  • 1. Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated Kinase 1/2 Activation.
    Koral K; Haynes M; Bowen WC; Orr A; Mars W; Michalopoulos GK
    Am J Pathol; 2018 Sep; 188(9):2074-2086. PubMed ID: 30126548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte-specific protein 1: a novel regulator of hepatocellular proliferation and migration deleted in human hepatocellular carcinoma.
    Koral K; Paranjpe S; Bowen WC; Mars W; Luo J; Michalopoulos GK
    Hepatology; 2015 Feb; 61(2):537-47. PubMed ID: 25234543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte-Specific Protein-1 Suppresses Xenobiotic-Induced Constitutive Androstane Receptor and Subsequent Yes-Associated Protein-Activated Hepatocyte Proliferation.
    Koral K; Bhushan B; Orr A; Stoops J; Bowen WC; Copeland MA; Locker J; Mars WM; Michalopoulos GK
    Am J Pathol; 2022 Jun; 192(6):887-903. PubMed ID: 35390317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
    Zahavi T; Lanton T; Divon MS; Salmon A; Peretz T; Galun E; Axelrod JH; Sonnenblick A
    Oncotarget; 2016 Jan; 7(4):4860-70. PubMed ID: 26695439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CARMIL1 regulates liver cancer cell proliferation by activating the ERK/mTOR pathway through the TRIM27/p53 axis.
    Ge Y; Xiao B; Zhao R; Li B; Yang S; He KF; Gu HJ; Zuo S
    Int Immunopharmacol; 2024 Jun; 134():112139. PubMed ID: 38739978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
    Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
    Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
    Wei CT; Chen LC; Hsiang YP; Hung YJ; Chien PH; Pan HL; Chen YJ
    Anticancer Res; 2019 Feb; 39(2):695-701. PubMed ID: 30711947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
    Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
    Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration.
    Russell JO; Ko S; Saggi HS; Singh S; Poddar M; Shin D; Monga SP
    Am J Pathol; 2018 Jun; 188(6):1389-1405. PubMed ID: 29545201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
    Manov I; Pollak Y; Broneshter R; Iancu TC
    FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of p53 After Irradiation Impairs the Regenerative Capacity of the Mouse Liver.
    Urabe M; Hikita H; Saito Y; Kudo S; Fukumoto K; Mizutani N; Myojin Y; Doi A; Sato K; Sakane S; Makino Y; Kodama T; Sakamori R; Tatsumi T; Takehara T
    Hepatol Commun; 2022 Feb; 6(2):411-422. PubMed ID: 34585534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
    Shi JH; Liu SZ; Wierød L; Scholz H; Anmarkrud JA; Huitfeldt HS; Zhang SJ; Line PD
    J Surg Oncol; 2013 Mar; 107(4):393-401. PubMed ID: 22927239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sorafenib on murine liver regeneration.
    Hora C; Romanque P; Dufour JF
    Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.